Torok Jordan A, Gu Lin, Tandberg Daniel J, Wang Xiaofei, Harpole David H, Kelsey Chris R, Salama Joseph K
Department of Radiation Oncology, Duke University Medical Center, Durham, NC.
Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC.
Clin Lung Cancer. 2017 Jan;18(1):e57-e70. doi: 10.1016/j.cllc.2016.06.011. Epub 2016 Jul 5.
Patients with limited metastases, oligometastases (OMs), might have improved outcomes compared with patients with widespread distant metastases (DMs). The incidence and behavior of OMs from non-small-cell lung cancer (NSCLC) need further characterization.
The medical records of patients who had undergone surgery for stage I-III NSCLC from 1995 to 2009 were retrospectively reviewed. All information pertaining to development of the first metastatic progression was recorded and analyzed. Patients with DMs were categorized into OMs (1-3 lesions potentially amenable to local therapy) and DM subgroups.
Of 1719 patients reviewed, 368 (21%) developed DMs with a median follow-up period of 39 months. A single lesion was diagnosed in 115 patients (31%) and 69 (19%) had 2 to 3 lesions (50% oligometastatic). The median survival from the DM diagnosis for oligometastatic and diffuse DM was 12.4 and 6.1 months, respectively (hazard ratio, 0.54; 95% confidence interval, 0.42-0.68; P < .001). Patients with a single metastasis had the longest median survival at 14.7 months. Younger age, OM, the use of chemotherapy for the primary tumor, and DM detection by surveillance imaging were independently associated with improved survival.
DMs and OMs are common in surgically managed NSCLC. Overall survival appears to be prolonged with OM.
与广泛远处转移(DMs)的患者相比,转移灶局限的寡转移(OMs)患者可能有更好的预后。非小细胞肺癌(NSCLC)寡转移的发生率和行为需要进一步明确。
回顾性分析1995年至2009年接受I - III期NSCLC手术患者的病历。记录并分析所有与首次转移进展相关的信息。将发生DMs的患者分为OMs(1 - 3个可能适合局部治疗的病灶)和DM亚组。
在1719例接受回顾的患者中,368例(21%)发生了DMs,中位随访期为39个月。115例患者(31%)诊断为单个病灶,69例(19%)有2至3个病灶(50%为寡转移)。寡转移和弥漫性DM患者从DM诊断开始的中位生存期分别为12.4个月和6.1个月(风险比,0.54;95%置信区间,0.42 - 0.68;P <.001)。单个转移灶患者的中位生存期最长,为14.7个月。年轻、OM、对原发肿瘤使用化疗以及通过监测影像检测到DM与生存期改善独立相关。
DMs和OMs在接受手术治疗的NSCLC中很常见。OM似乎可延长总生存期。